The trial is conducted at the Mays Cancer Center, part of the University of Texas at San Antonio’s Health Science Center.

A new research paper was published in Volume 17, Issue 12 of Aging-US on December 1, 2025, titled “CD47 antisense oligonucleotide treatment improves glucose homeostasis and alleviates dyslipidemia in ...

“Together, these findings support a beneficial role for CD47 knockdown in alleviating age-associated metabolic dysfunction through coordinated effects across multiple organs” “Together, these findings ...

Biosion, Inc. ("Biosion"), a global, clinical-stage biotechnology company developing innovative antibody-based therapeutics, today announced that the first patient has been dosed in a Phase 1a/1b ...

本研究针对免疫性溶血后红细胞残骸清除机制不明的问题，通过体内外模型联合蛋白质组学分析，揭示了E3泛素连接酶MARCH1介导的CD47泛素化降解是促进巨噬细胞吞噬溶血红细胞的关键机制。该发现阐明了红细胞清除的新通路，为溶血相关疾病的治疗提供了潜在靶 ...

The start-up Function will send practically anyone to a lab for extensive medical testing, no physical required. Is that a good thing? By Kristen V. Brown As Kimberly Crisp approached middle age, ...

本综述系统阐述了抗CD47抗体修饰的顺铂负载介孔二氧化硅纳米颗粒（CDDP@MSN-Anti-CD47）在结直肠癌（CRC）治疗中的突破性进展。该研究创新性地将化疗药物顺铂（CDDP）与免疫检查点阻断剂抗CD47抗体整合于纳米载体，通过靶向递送诱导免疫原性细胞死亡（ICD）并 ...

当前，PD-(L)1抑制剂行业正处于发展转折点。翰思艾泰（3378.HK）以颠覆性创新打破困局，凭借两款重磅管线HX009、HX044的突破性进展，让CD47强势崛起，正式开启肿瘤免疫治疗的全新篇章。 作为CD47新机制的开拓者与领航者，翰思艾泰跳出传统“别吃我”信号阻断的 ...

业内人士指出，全球首创的分子设计（强PD-1+弱CD47融合蛋白）和突破性的安全性（解决CD47靶点血液毒性痛点），同时通过差异化临床策略避开红海竞争，聚焦未被满足的临床需求，HX009有望成为肿瘤免疫治疗领域的FIC，为免疫治疗耐药患者和罕见肿瘤患者带来新希望。